Journal article

Non-compliance: the Achilles' heel of anti-fracture efficacy

E Seeman, J Compston, J Adachi, ML Brandi, C Cooper, B Dawson-Hughes, B Jonsson, H Pols, JA Cramer

OSTEOPOROSIS INTERNATIONAL | SPRINGER LONDON LTD | Published : 2007

Abstract

About 50% of patients fail to comply or persist with anti-osteoporosis treatment regimens within 1 year. Poor compliance is associated with higher fracture rates. Causes of poor compliance are unknown. As it is not possible to predict poor compliance, close monitoring of compliance is needed. Despite evidence supporting the anti-fracture efficacy of several pharmacological agents, approximately 50% of patients do not follow their prescribed treatment regimen and/or discontinue treatment within 1 year. Poor compliance is associated with higher fracture rates and increased morbidity, mortality and cost. However, as poor compliance, even to placebo, is associated with adverse outcomes, the high..

View full abstract

University of Melbourne Researchers